TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Brief Summary: Scleroderma is a rare, long-term autoimmune disease in which normal tissue is replaced with dense, thick fibrous tissue. Normally, the immune system helps defend the body against disease and infection. In people with scleroderma, the immune system triggers fibroblast cells to produce too much of the protein collagen. The extra collagen becomes deposited in the skin and organs, causing hardening and thickening that is similar to the scarring process. Although scleroderma most often affects the skin, it also can affect other parts of the body, including the lungs, and in its most severe forms scleroderma can be life-threatening. Scleroderma-related interstitial lung disease is one example of a life-threatening scleroderma condition. In people with symptomatic scleroderma-related interstitial lung disease, scarring occurs in the delicate lung tissue, compromising lung function. The purpose of this study is to determine whether people with symptomatic scleroderma-related interstitial lung disease experience more respiratory benefits from treatment with a 2-year course of mycophenolate mofetil or treatment with a 1-year course of oral cyclophosphamide.


Options:
A: Arm Label: stem cell trasplantation; Type: EXPERIMENTAL; Interventions: Procedure: stem cell transplantation | Arm Label: standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard of care | Intervention Type: DRUG; Name: standard of care; Assigned to Arm(s): standard of care | Intervention Type: PROCEDURE; Name: stem cell transplantation; Assigned to Arm(s): stem cell trasplantation
B: Arm Label: Mycophenolate Arm; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil | Arm Label: Cyclophosphamide Arm; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Drug: Placebo | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Arm | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cyclophosphamide Arm
C: Arm Label: Cylophosphamide; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cylophosphamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: mHSCT; Type: EXPERIMENTAL; Interventions: Biological: mHSCT | Arm Label: cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide | Intervention Type: BIOLOGICAL; Name: mHSCT; Assigned to Arm(s): mHSCT | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): cyclophosphamide

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)
Brief Summary: Scleroderma is a rare, long-term autoimmune disease in which normal tissue is replaced with dense, thick fibrous tissue. Normally, the immune system helps defend the body against disease and infection. In people with scleroderma, the immune system triggers fibroblast cells to produce too much of the protein collagen. The extra collagen becomes deposited in the skin and organs, causing hardening and thickening that is similar to the scarring process. Although scleroderma most often affects the skin, it also can affect other parts of the body, including the lungs, and in its most severe forms scleroderma can be life-threatening. Scleroderma-related interstitial lung disease is one example of a life-threatening scleroderma condition. In people with symptomatic scleroderma-related interstitial lung disease, scarring occurs in the delicate lung tissue, compromising lung function. The purpose of this study is to determine whether people with symptomatic scleroderma-related interstitial lung disease experience more respiratory benefits from treatment with a 2-year course of mycophenolate mofetil or treatment with a 1-year course of oral cyclophosphamide.


Options:
A: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: 1197 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 1197 mg/day pirfenidone, 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Mycophenolate Arm; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil | Arm Label: Cyclophosphamide Arm; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Drug: Placebo | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Arm | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cyclophosphamide Arm
D: Arm Label: Active Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): Active Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Parallel-group, Rater-blinded Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis Plus a Long Term Extension Period
Brief Summary: Primary objective was to assess the effectiveness evaluated by the time to failure of two doses of teriflunomide in comparison to interferon beta-1a in participants with relapsing Multiple Sclerosis \[MS\].

Secondary objectives were:

* To assess the effect of the two doses in comparison to interferon beta-1a on:

  * Frequency of relapses,
  * Fatigue,
  * Participant's satisfaction with treatment.
* To evaluate the safety and tolerability of the two doses in comparison to interferon beta-1a.

The study consisted of a core treatment period with a common end date defined as 48 weeks after randomization of the last participant, followed by an optional long-term extension treatment period until teriflunomide is commercially available in accordance with local regulations.


Options:
A: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo
B: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
C: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: teriflunomide (HMR1726) | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: teriflunomide (HMR1726) | Intervention Type: DRUG; Name: teriflunomide (HMR1726); Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg
D: Arm Label: Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Teriflunomide, Drug: Placebo | Arm Label: Teriflunomide 7 mg/7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg/14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg, Teriflunomide 14 mg/14 mg, Teriflunomide 7 mg/7 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reduction of Myocardial Infarction by Preconditioning in Patients With Ruptured Abdominal Aortic Aneurysm
Brief Summary: Preconditioning in patients treated for elective abdominal aneurysm showed that the rate of perioperative myocardial infarction could be reduced by 80 %(ARR from 27% to 5%). Precondition where performed by 10 minutes of clamping of each iliac arteries before clamping the abdominal aorta. Human studies in cardiac patients have shown promising results with precondition. Instead of clamping arteries they have all performed the procedure by inflating a blood pressure cuff above arterial pressure on a arm.

The investigators want to investigate if preconditioning induced by a blood pressure cuff on a arm can reduce the perioperative rate of myocardial infarction in patients open operated for ruptured abdominal aortic aneurysm.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Procedure: clamping with pre-conditioning (PCl) | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: clamping with pre-conditioning (PCl); Assigned to Arm(s): Arm 1
B: Arm Label: Precondition; Type: EXPERIMENTAL; Interventions: Procedure: Precondition | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Precondition; Assigned to Arm(s): Precondition
C: Arm Label: Remote ischaemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischaemic preconditioning | Arm Label: Control to RIPC; Type: SHAM_COMPARATOR; Interventions: Procedure: Control to RIPC | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic preconditioning | Intervention Type: PROCEDURE; Name: Control to RIPC; Assigned to Arm(s): Control to RIPC
D: Arm Label: Remote ischaemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischaemic preconditioning | Arm Label: Control to remote preconditioning group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic preconditioning

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Parallel-Group, Placebo-Control, Double-Blind Trial Comparing the Efficacy and Safety of Nutritional Supplementation Containing Omega 3 Fatty Acids and Gamma Linoleic Acid, for Treatment of Keratoconjunctivitis Sicca in Post-Menopausal Females
Brief Summary: The purpose of this study is to determine the effectiveness of a nutritional supplement in post-menopausal women age 40 or older with moderate to severe dry eyes. This study is being conducted to determine if signs and symptoms of dry eye will improve with the use of this nutritional supplement.


Options:
A: Arm Label: SB; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sea buckthorn (Hippophaë rhamnoides) oil | Arm Label: PL; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo comparison | Intervention Type: DIETARY_SUPPLEMENT; Name: Sea buckthorn (Hippophaë rhamnoides) oil; Assigned to Arm(s): SB | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo comparison; Assigned to Arm(s): PL
B: Arm Label: Normal; Type: N/A; Interventions: N/A | Arm Label: Dry Eye Disease; Type: N/A; Interventions: N/A
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Inactive Capsule | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Hydroeye | Intervention Type: DIETARY_SUPPLEMENT; Name: Hydroeye; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Inactive Capsule; Assigned to Arm(s): 1
D: Arm Label: Omega-3 supplements; Type: EXPERIMENTAL; Interventions: Drug: Omega-3 supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega-3 supplements; Assigned to Arm(s): Omega-3 supplements | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects Of Pregabalin On Sleep Maintenance In Subjects With Fibromyalgia Syndrome And Sleep Maintenance Disturbance: A Randomized Placebo-Controlled 2-Way Crossover Polysomnography Study
Brief Summary: The purpose of the study is to demonstrate the effect of Lyrica on Wake after sleep onset in subjects with fibromyalgia with sleep maintenance disturbance (on polysomnogram)


Options:
A: Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: Lyrica; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Lyrica | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intramuscular ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Critical Limb Ischemia (Cli)
Brief Summary: This clinical trial aims to study the safety and efficacy of adult mesenchymal stem cells in critical limb ischemia.


Options:
A: Arm Label: MultiGeneAngio; Type: EXPERIMENTAL; Interventions: Biological: MultiGeneAngio | Intervention Type: BIOLOGICAL; Name: MultiGeneAngio; Assigned to Arm(s): MultiGeneAngio
B: Intervention Type: GENETIC; Name: Autologous bone marrow cells; Assigned to Arm(s): N/A
C: Arm Label: GM-CSF; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulocyte-Macrophage Stimulating Factor (GM-CSF); Assigned to Arm(s): GM-CSF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: mesenchymal stem cells; Type: EXPERIMENTAL; Interventions: Drug: mesenchymal stem cells | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Plasmalyte A | Intervention Type: DRUG; Name: mesenchymal stem cells; Assigned to Arm(s): mesenchymal stem cells | Intervention Type: DRUG; Name: Plasmalyte A; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intramuscular ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Critical Limb Ischemia (Cli)
Brief Summary: This clinical trial aims to study the safety and efficacy of adult mesenchymal stem cells in critical limb ischemia.


Options:
A: Arm Label: mesenchymal stem cells; Type: EXPERIMENTAL; Interventions: Drug: mesenchymal stem cells | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Plasmalyte A | Intervention Type: DRUG; Name: mesenchymal stem cells; Assigned to Arm(s): mesenchymal stem cells | Intervention Type: DRUG; Name: Plasmalyte A; Assigned to Arm(s): Placebo
B: Arm Label: autologous purified CD34+ cell; Type: EXPERIMENTAL; Interventions: Other: autologous purified CD34+ cells | Arm Label: autologous PB-MNC; Type: ACTIVE_COMPARATOR; Interventions: Other: autologous peripheral blood mononuclear cells | Intervention Type: OTHER; Name: autologous purified CD34+ cells; Assigned to Arm(s): autologous purified CD34+ cell | Intervention Type: OTHER; Name: autologous peripheral blood mononuclear cells; Assigned to Arm(s): autologous PB-MNC
C: Arm Label: ALD-301; Type: EXPERIMENTAL; Interventions: Biological: ALD-301 | Arm Label: Placebo (vehicle); Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (vehicle) | Intervention Type: BIOLOGICAL; Name: ALD-301; Assigned to Arm(s): ALD-301 | Intervention Type: BIOLOGICAL; Name: Placebo (vehicle); Assigned to Arm(s): Placebo (vehicle)
D: Arm Label: 4times injection; Type: EXPERIMENTAL; Interventions: Biological: 4times injection | Arm Label: one injection; Type: EXPERIMENTAL; Interventions: Biological: stem cell transplantation | Intervention Type: BIOLOGICAL; Name: 4times injection; Assigned to Arm(s): 4times injection | Intervention Type: BIOLOGICAL; Name: stem cell transplantation; Assigned to Arm(s): one injection

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intramuscular ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Critical Limb Ischemia (Cli)
Brief Summary: This clinical trial aims to study the safety and efficacy of adult mesenchymal stem cells in critical limb ischemia.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
B: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: bone marrow stem cells intraarterial; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow stem cells (BMC) | Arm Label: tissue repair cells intramuscular; Type: ACTIVE_COMPARATOR; Interventions: Biological: tissue repair cells (TRC) | Arm Label: tissue repair cells intraarterial; Type: ACTIVE_COMPARATOR; Interventions: Biological: tissue repair cells (TRC) | Arm Label: bone marrow stem cells intramuscular; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow stem cells (BMC) | Intervention Type: BIOLOGICAL; Name: tissue repair cells (TRC); Assigned to Arm(s): tissue repair cells intraarterial, tissue repair cells intramuscular | Intervention Type: BIOLOGICAL; Name: bone marrow stem cells (BMC); Assigned to Arm(s): bone marrow stem cells intraarterial, bone marrow stem cells intramuscular
C: Intervention Type: GENETIC; Name: Autologous bone marrow cells; Assigned to Arm(s): N/A
D: Arm Label: mesenchymal stem cells; Type: EXPERIMENTAL; Interventions: Drug: mesenchymal stem cells | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Plasmalyte A | Intervention Type: DRUG; Name: mesenchymal stem cells; Assigned to Arm(s): mesenchymal stem cells | Intervention Type: DRUG; Name: Plasmalyte A; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Multi-Center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)
Brief Summary: Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are medical conditions that occur when there is severe inflammation and increased fluids in both lungs, making it difficult for the lungs to function properly. Hospital treatment for a person with ALI/ARDS often includes the use of a breathing machine, or ventilator, until the person is able to breathe without assistance. Initiating proper nutrition through a feeding tube early in a person's hospital stay may help to improve recovery, but the optimal timing, composition, and amount of feeding treatments remain unknown. This study will evaluate whether early or delayed full-calorie feeding through a feeding tube is more effective in reducing recovery time and increasing survival rates in people with ALI/ARDS.


Options:
A: Arm Label: Normocaloric feeding; Type: NO_INTERVENTION; Interventions: Other: Hypocaloric feeding | Intervention Type: OTHER; Name: Hypocaloric feeding; Assigned to Arm(s): Normocaloric feeding
B: Intervention Type: DRUG; Name: low calorie, low nitrogen parenteral nutrition for patient with NRS score 3; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Full Feeding | Intervention Type: BEHAVIORAL; Name: Minimal (Trophic) Feeding; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Full Feeding; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Full Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Full Feeding, Dietary Supplement: Placebo | Intervention Type: BEHAVIORAL; Name: Minimal (Trophic) Feeding; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Full Feeding; Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acids and Antioxidant Supplements; Assigned to Arm(s): 1, 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3, 4

Answer: C